肝脏免疫耐受与肝细胞癌:病理生理机制及治疗前景
综述阐述肝脏免疫耐受机制及其在肝细胞癌发生中的作用,指出肝细胞癌是免疫检查点抑制剂治疗的候选病种。多项II/III期研究正在进行,仅tremelimumab II期和Nivolumab I/II期(CheckMate-040)有最终结果,后者前景可期但需III期确认。
要点
- 肝细胞癌诊断时70%患者仅能接受姑息治疗,治疗选择极少。
- 肝脏免疫耐受与慢性肝病及肝癌发生相关,支持免疫检查点抑制剂应用。
- Nivolumab I/II期结果前景可期,但需正在进行的III期研究确认。
核心结论
- 免疫治疗为肝细胞癌患者带来新希望,但仍需严格评估以确认其价值。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
主要发现
- 肝细胞癌诊断时70%患者仅能接受姑息治疗,治疗选择极少。
- 肝脏免疫耐受因抗原持续大量流入而特别发达,其失调参与慢性肝病及肝癌发生。
- 目前仅有tremelimumab II期和Nivolumab I/II期(CheckMate-040)最终结果可用,后者前景可期。
临床怎么用
- 肝细胞癌可考虑免疫检查点抑制剂(靶向CTLA-4和PD-L1/PD-1)治疗,但需在肝功能不全背景下评估安全性和疗效。
局限性
- 肝脏特殊免疫环境及肝细胞癌常合并肝功能不全,需专门研究新治疗的安全性和疗效。
- 多数免疫治疗研究尚在进行中,仅少数有最终结果,需III期研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At the moment of the diagnosis of hepatocellular carcinoma (HCC), 70% of patients have only access to palliative treatments, with very few therapeutic options. Liver immunology is very specific, and liver immunotolerance is particularly developed because of the constant and massive influx of antigens. Deregulation of hepatic immunotolerance is implicated in chronic liver diseases development and particularly in liver carcinogenesis. For these reasons, HCC may be an excellent candidate for anticancer immunotherapies such as immune checkpoint inhibitors targeting CTLA-4 and PD-L1/PD-1. Nonetheless, because of the specific immune environment of the liver and the frequent association of HCC with hepatocellular insufficiency, the safety and the efficacy of these new treatments have to be properly studied in this situation. Thus, multiple phase II and III studies are in progress studying immune checkpoint inhibitor monotherapies, combination of different immunotherapies or local strategies such as transarterial chemoembolization combined with immune checkpoint inhibitors. Currently, only the final results of the tremelimumab phase II and the Nivolumab phase I/II study (CheckMate-040) are available. The latter is promising but need to be confirmed by the ongoing phase III studies to confirm the place of immunotherapy in the treatment of HCC. With many new molecular targets and therapeutic combination, immunotherapy represents a new hope in treating HCC patients although serious evaluation is still needed to confirm its interest.
引用
- Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer. 2017. PMID: 29145036. doi:10.1016/j.ejca.2017.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。